ly3537982
Small moleculeexperimental
Clinical trial activity
13 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jul 19, 2021 (NCT04956640)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Healthy Volunteers · Phase 1
- Hepatic Insufficiency · Phase 1
- Neoplasm Metastasis · Phase 3
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Renal Insufficiency · Phase 1
Mechanism of action
- GTPase KRasINHIBITOR
KRAS inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N1CCN2C(=O)c3cc(F)c(-c4ccc(F)c5sc(N)c(C#N)c45)c(Cl)c3OCC[C@H]2C1- Mol. weight
- 528.97 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068410 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07227025 | Phase 1/Phase 2 (Phase 2) | Dec 22, 2025 | — |
| NCT07124013 | Phase 1 | Sep 16, 2025 | Eli Lilly |
| NCT07137689 | Phase 1 | Aug 18, 2025 | Eli Lilly |
| NCT07044271 | Phase 1 | Jul 11, 2025 | Eli Lilly |
| NCT06890598 | Phase 3 | Mar 27, 2025 | AstraZeneca, Eli Lilly |
| NCT06719128 | Phase 1 | Dec 31, 2024 | Eli Lilly |
| NCT06235983 | Phase 1 | Feb 29, 2024 | Eli Lilly |
| NCT06119581 | Phase 3 | Jan 3, 2024 | Eli Lilly, Loxo Oncology |
| NCT06111521 | Phase 1 | Oct 27, 2023 | Eli Lilly, Loxo Oncology |
| NCT05901311 | Phase 1 | Jun 5, 2023 | Eli Lilly, Loxo Oncology |
| NCT05860933 | Phase 1 | May 8, 2023 | Eli Lilly, Loxo Oncology |
| NCT05824858 | Phase 1 | Apr 12, 2023 | Eli Lilly, Loxo Oncology |
| NCT04956640 | Phase 1 | Jul 19, 2021 | Eli Lilly, Loxo Oncology |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 12 | 12 | 2 | 2021 |
| Loxo Oncology | For profit | 6 | 0 | 2 | 2021 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1